Ensysce Biosciences Shifts Strategy: President Holds Convertible Preferred After Cy Biopharma Merger, Betting on Orphan‑Drug Breakthrough.
Ensysce’s insider move reveals a strategic pivot: merging with Cy Biopharma to unlock orphan‑drug Cy 200, boosting pain‑therapy prospects and equity value.
3 minutes to read